Abstract
Pyruvate carboxylase (PC) is an enzyme catalyzing the carboxylation of pyruvate to oxaloacetate. The enzymatic generation of oxaloacetate, an intermediate of the Krebs cycle, could provide the cancer cells with the additional anaplerotic capacity and promote their anabolic metabolism. Recent studies revealed that several types of cancer cells express PC. The gained anaplerotic capability of cells mediated by PC correlates with their expedited growth, higher aggressiveness, and increased metastatic potential. By immunohistochemical staining and immunoblotting analysis, we investigated PC expression among samples of different types of human brain tumors. Our results show that PC is expressed by the cells in glioblastoma, astrocytoma, oligodendroglioma, and meningioma tumors. The presence of PC in these tumors suppose that PC could support the anabolic metabolism of their cellular constituents by its anaplerotic capability.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The transformed metabolism of cancer cells is adapted to sustain their energy needs and sustain the conversion and/or biosynthesis of the compounds crucial for their growth and division. The cytosolic processes of glucose utilization by glycolysis [1] and pentose-phosphate pathway [2] should be supplemented by functional mitochondrial metabolism, especially reactions of the Krebs cycle [3]. Typical feature of the transformed metabolism of cancer cells is increased production of lactate by intensified flux of glucose through glycolytic pathway, so-called Warburg effect [1, 4, 5]. Even higher flux from glucose derived carbon atoms through pyruvate to lactate is anticipated in the cancer cells their capacity to oxidaze pyruvate is limited due to inhibition of pyruvate dehydrogenase complex. Although, several intermediates of the Krebs cycle are the indispensable substrates for encouraging the biosynthetic reaction. The withdrawal of the Krebs cycle intermediates has to be replenished by an anaplerotic process to maintain mitochondrial metabolism. Only a limited number of reactions is considered to possess the anaplerotic role [6]. Among them, the generation of 2-oxoglutarate from glutamine or glutamate was considered as the most significant anaplerotic process in the cancer cells [7,8,9]. In this respect, the catabolism of glutamate and glutamine, which are taken up from the cellular milieu, could impart the cells with both carbon skeleton and reduced nitrogen [10]. The recent studies with the cultured cancer cells and on the animal models revealed that also the anaplerotic role of pyruvate carboxylase (PC) could significantly participate in sustaining the metabolism and survival of cancer cells and the growth of tumors [11,12,13,14,15,16,17]. PC is mitochondrial protein, which have to be for its molecular activity converted from apoenzym to holoenzyme form by its biotinylation [18].
The carboxylation of pyruvate to oxaloacetate by PC could provide the cells with the capability to convert pyruvate, an intermediate of glycolysis, to a Krebs cycle member [19]. Oxaloacetate could be converted further to several compounds such as phosphoenolpyruvate, citrate, aspartate, malate or pyruvate [20]. Together with aspartate and malate, citrate could impact the cellular metabolism in mitochondrial and cytosolic compartments. Citrate transported into the cytosol is the significant source of the cytosolic acetyl-CoA for synthesizing fatty acids and cholesterol [21], while malate and aspartate also participate in the electron shuttle process [22]. The generation of phosphoenolpyruvate is an essential reaction for sustaining gluconeogenesis in liver and kidney cells [23].
Since anaplerotic reactions profoundly impact cellular metabolism, the possibility of targeting the critical anaplerotic enzymes could provide new therapeutic approaches in managing cancer diseases. While the results of the experiments on the cell cultures and animal models [14, 16, 24, 25] could provide valuable hints about the role of PC as the putative target for prognosis and therapy, only the rigorous testing of the human cancers might confirm the presence of PC in different types of tumors. Therefore, we investigated by the immunoblotting methods the presence of PC among the different types of human brain tumor samples, which were surgically removed from the patients during the therapy. We provide pieces of evidence that PC is expressed in different types of human brain tumors and in the healthy brain.
Results
The suggested important role of PC in supporting the metabolism and features of cancer cells in culture and animals evokes the question to which extent PC is also expressed among human tumors in vivo. To investigate the presence of PC in several types of brain tumors (Table 1) obtained from the patients after the surgical resections, we applied immunoprobing-based analysis.
To exploit the capability of antibodies, those were initially derived against PC isolated from bovine liver [26], also to detect the human ortholog, their specificity was tested. By immunoprobing of the proteins in glioblastoma tumor homogenate, the antibodies gave a positive signal (Fig. 1a/A, b/A), which in the case of Western blot analysis corresponds to the protein with a relative molecular mass of 125 kDa (Fig. S1). The treatment of the homogenate with the streptavidin agarose beads prevented the detection of the signal (Figs. 1a/B, b/B) that reappeared again after elution of proteins from streptavidin agarose beads by applied biotin (Fig. 1b/C, b/C). As a positive control for a dot blot analysis, the purified pyruvate carboxylase from the bovine liver was used (Figs. 1a/D, 2 PC(pur)). The biotin eluted fraction was also examined for PC activity. Indeed, the enzymic activity of PC was detected (data not shown).
The Western blot analysis shows that PC is expressed among all of the tested protein extracts obtained from glioblastoma, astrocytoma, oligodendroglioma, and meningioma tumors; and also in protein lysates derived from the total human brain, cerebral cortex, and meninges (Fig. 2). The glioblastoma sample in the blot (Fig. 2; GBM) corresponds to spot A1 in Fig. 3, such as other samples are shown in dot blot: astrocytoma (Fig. 2; AST) in spot B2, oligodendroglioma (Fig. 2; ODG) in spot C4, and meningioma (Fig. 2; MNG) in spot D4 in Fig. 3.Purified bovine pyruvate carboxylase and lysate of hepatocarcinoma cells (Fig. 2) were used as positive controls. Indeed, the estimated relative molecular mass of the visualized bands corresponds mass of PC (125 kDa). Both proteins, GAPDH and β-actin (Fig. 2), were visualized as the loading controls.
The qualitative analysis of the obtained chemiluminescent signal revealed the ubiquitous presence of signal corresponding to PC expression among tested protein extracts prepared from glioblastoma (Fig. 3a, A1–A10), astrocytoma (Fig. 3a, B1–B10), oligodendroglioma (Fig. 3a, C1–C7) and meningioma (Fig. 3a, samples D1–D7) tumors. Purified pyruvate carboxylase was used as a positive control (Fig. 3a, sample E1). The recorded chemiluminescent signal was observable from all samples with varying intensities of quantified signal within the particular groups of the samples (Fig. 3b). Comparison of quantified chemiluminescent signal in different types of tested brain tumors did not revealed any statistical differences in expression levels of PC among them.
Immunofluorescence method was applied to visualize the expression of PC among the cells in glioblastoma (Fig. 4, PC) and in astrocytoma (Fig. 5, PC) sections. Three samples of different glioblastoma and astrocytoma samples were analyzed for immunohistochemistry and one sample of them is presented. In sections of both tumors types the green fluorescence signal was visible when observed by fluorescence microscopy. Indeed, mouse anti-glial fibrillary acidic protein (GFAP) IgG molecules in combination with the secondary antibodies, which were conjugated to Alexa fluor 633 (red fluorescence signal), provided identification of GFAP positive cells (Fig. 4, GFAP). The colocalization of GFAP and PC positive signals appeared in yellow (Fig. 4, Merge). DAPI intercalating fluorochrome was used to visualized the cell nuclei (Figs. 4, DAPI; 5, DAPI). In the case of the negative controls, when only the mixture of secondary antibodies was applied, the fluorescent signal was not observable (Figs. 4, 5 negative control). For this reason, it can be expected that the observed fluorescence signal corresponds with the presence of PC in the sections from glioblastoma and astrocytoma.
Discussion
With the aim to assign the expression of PC among different types of human brain tumors, we tested the presence of PC in protein extracts derived from the surgically obtained specimens from human glioblastoma, astrocytoma, oligodendroglioma, and meningioma tumors. The applied immunodetection methods on tumor homogenate proteins revealed the expression of PC in all tested samples. These results provide the hint that PC could be ubiquitously expressed in human glioblastoma, astrocytoma, oligodendroglioma, and meningioma tumors (Figs. 2, 3). Furthermore, the Western blot analysis shows that PC is also present in the human brain and meninges forming cells (Fig. 2).
We assume that the immunoblotting signal for PC is higher in the tumors compared to the healthy samples due to the higher demands of tumor cells for anaplerotic metabolism to support their rapid growth and multiplication [27]. The increased anaplerotic capacity of tumor cells facilitated by PC, might support the increased demand for synthesis of fatty acid and cholesterol [19,20,21]. These biosynthetic processes require the supply of acetyl-CoA in cytosol. In this respect, the withdrawal of mitochondria-born citrate could be employed. Therefore, contributing of PC to increase the anaplerotic capability of tumor cells could prevent the collapse of the Krebs cycle and/or mitochondiral metabolism [21].
The presented results of immunofluorescent experiments show that the PC is expressed to different extents among glioblastoma and astrocytoma tumor-forming cells (Figs. 4, 5). The fluorescent signal of PC is localized in the proximity of the cell nuclei and observable in the vast majority of glioblastoma-forming cells and a significant proportion of astrocytoma cells. The levels of PC can vary in different ranges from tumor to tumor and at the same time in the same types of tumor from patient to patient as we showed in dot blot (Fig. 3) and also in immunocytochemistry (Figs. 4, 5). It was shown that GFAP expression in glioblastoma tumors is increased in comparison to other brain cancer types [28]. Indeed, GFAP-positive cells accounted for the majority of the glioblastoma-forming cells (Fig. 4).
The expression of PC was already confirmed in several other human cancer types, e.g., small cell lung cancer [13], breast [14], colorectal [29], pancreatic [30], and prostate [31] cancers. The complementary studies with either cultured cancer cells or on animal models revealed that the anaplerotic role of the PC supports several cellular processes [15, 25, 32] with an impact on the growth [17], progression [29], resistance, and metastatic capability [14, 25] of tumors.
The anabolic metabolism of cancer cells is dependent on the cellular capability to restore the levels of the intermediates of the Krebs cycle (Fig. 6) by anaplerotic processes[33]. Only a limited number of reactions is considered to possess the anaplerotic role. The most important anaplerotic process in cancer cells is the generation of 2-oxoglutarate from extracellularly originating glutamine. In this respect, the catabolism of glutamine, which is taken up from the cellular milieu, could impart the cells with both carbon skeleton and reduced nitrogen. Increased consumption of glutamine by different brain tumors, including glioblastoma, was documented by a previous metabolomic study [34]. The recent studies with the cultured cancer cells and animal models revealed that the anaplerotic role of PC could significantly participate in sustaining the metabolism and survival of cancer cells and the growth of tumors, especially if glutamine supply is insufficient [11]. The remaining three anaplerotic processes include the conversion of propionyl-CoA to succinyl-CoA and aspartate to oxaloacetate or fumarate through either adenylosuccinate or fumarylacetoacetate. However, the importance of those remaining processes for the metabolism of cancer cells has not been fully elicited yet.
PC expression in human tumors is a prerequisite for the cells to explore its enzymatic possibility. The regulation of the PC expression is rather complex [35], and includes converting apoenzyme to its active biotinylated holoenzyme form. The disappearance of the immunoprobing signal of PC from the glioblastoma homogenate treated with streptavidin indicates that the PC is present in biotinylated (Fig. 1), enzymatically active form. Deprivation of glutamine could also promote increased PC activity and, therefore, could support the independence of cellular anaplerotic metabolism on extracellularly available glutamine [11]. Since several approaches to target the glutamine metabolism of cancer cells are under investigation and testing [7, 8], the possibility of cancer cells to supplement or substitute the anaplerotic role of glutamine by PC facilitated anaplerotic metabolism might be taken into account. In this respect, the knowledge about the expression of PC in particular types of tumors could contribute to proposing and designing the therapeutic approaches affecting cancer cells characteristics by altering their metabolism [36].
Methods
The Ethics Committee of the Jessenius Faculty of Medicine CU in Martin has approved the experiments with human samples under the code FK 75/2018. Informed consent was obtained from all subjects of this study and all participants have been performed in accordance with the Declaration of Helsinki. The selected characteristics of the patients, which are donors' brain tumor specimens and who had not previously received radiotherapy or chemotherapy, are in Table 1.
All biopsy tissues obtained during tumor resection were provided by Department of Neurosurgery (Roosevelt Hospital, Banská Bystrica, Slovakia) between November 2018 and September 2019 and were histologically confirmed according to the criteria of the used WHO Classification [37].
Homogenization and Production of Protein Extracts
For experiments were used ten samples of glioblastoma, ten of astrocytoma, seven of oligodendroglioma, and seven of meningioma obtained by biopsies. Immediately after surgery, the tumor was subdivided into several pieces and stored at − 80 °C. The tumor samples were used to prepare homogenates in the buffer consisting of 0.3 M sucrose, 5 mM EDTA, 0.3 mM phenylmethylsulfonyl fluoride, and 30 mM K2HPO4,/KH2PO4 with pH 7.0; according to a method already described [38].
Extraction of Biotin-Containing Proteins
The clarified glioblastoma homogenate was used to generate two fractions, either free or enriched with the biotin-containing proteins. The level of glioblastoma homogenate proteins was set to 1 µg/ml with Dulbecco’s Phosphate Buffered Saline (DPBS; D8537, Sigma). The biotin-containing proteins were extracted from lysates by the already used method [38]. Briefly, 150 µl of diluted lysate was incubated with 500 µl of streptavidin-agarose beads suspension (Thermo-Fisher) at room temperature for one hour. Subsequently, the suspension was centrifuged at 3000×g for 5 min, and supernatant-1 was collected. The sediment was washed twice with DPBS to remove unspecifically interacting proteins; those were collected and combined with supernatant-1. The generated supernatant-1 was depleted of biotin-containing proteins. The biotin-containing proteins were eluted from a complex with streptavidin agarose beads with DPBS supplemented with biotin (100 µg/ml). During incubation at room temperature for 30 min. After centrifugation of suspension at 3000×g for 5 min, supernatant-2 was collected. The proteins in the diluted glioblastoma homogenate, supernatant-1, and supernatant-2, were precipitated with acetone and collected by centrifugation at 12,000×g for 12 min. Supernatants were discarded, and air-dried pellets were resuspended in DPBS and used for further analysis.
Dot Blot Analysis
The clarified homogenates derived from brain and glioblastoma, astrocytoma, oligodendroglioma, and meningioma tumors were used to evaluate the expression of PC by adaptation of previously described dot blot method [38]. Briefly, 0.5 µg of protein were spotted on nitrocellulose membrane, and was probed with rabbit antiserum against pyruvate carboxylase diluted 1:200 in blocking solution overnight. The blocking solution (BS) consisting of Tris-buffered saline (TBS; 19.8 mM Tris, 136 mM NaCl, with pH adjusted to 7.5) supplemented 2% (W/W) albumin (BSA; Applichem) and 0.05% (W/V) Tween-20 (Sigma). Applied secondary antibodies were goat anti-rabbit IgG conjugated with horse-radish peroxidase diluted in BS 1:10,000. The chemiluminescent signal was recorded and subsequently the intensity of chemiluminescent signals was quantified by the Image Studio Lite version 5.2 software (LI-COR Biotechnology). The final values represent the intensity of the specific signal that was calculated by subtracting the background value from signal of the sample.
Cell Culturing and Preparation of Cell Lysate
For the study, we used human HepG2 hepatocarcinoma cell line (ATCC-HB-8065; DSMZ). The cells were cultured according to the supplier’s instructions.
The cells grown to 80% confluency were washed twice with ice-cold DPBS and subsequently, cells were lysed in ice-cold lysis buffer consisting of 30 mM TRIS with pH 7.6, supplemented with 150 mM NaCl, 1% (W/V) CHAPS (Sigma), and with 1% (V/V) of commercially available Halt™ protease inhibitor (Thermo-Scientific). Centrifugation at 10,000×g for 10 min was used for clarification of lysates. The generated supernatants were aliquoted and stored at − 20 °C before used.
Western Blot Analysis
The proteins were resuspended in loading buffer (300 mM TRIS, 300 mM dithiothreitol, 60% V/W glycerol, 0,3% V/W bromphenol blue, pH 6.8) were denatured by boiling for 5 min before they were loaded on 8% acrylamide gels for separation by SDS-PAGE method [39]. Separated proteins were electroblotted on the nitrocellulose membrane (Bio-Rad Laboratories), which were subsequently incubated in the BS at room temperature for one hour. The primary antibodies, rabbit anti-PC, were diluted in BS to a final ratio of 1:500 at 4 °C for overnight. After three washing steps, the solution of mouse anti-rabbit conjugated with POD in BS (final dilution ratio 1:10,000) was applied. After one hour of incubation at room temperature, the membrane was washed three times, and subsequently, a chemiluminescent signal was developed after soaking in SuperSignal West Pico Chemiluminescent Substrate solution (Thermo-Scientific) and recorded by Chemidoc XRS system (Bio-Rad Laboratories). Two loading controls were performed by visualization of β-actin (Santa Cruz Biotechnology) and GAPDH (Santa Cruz Biotechnology).
Immunohistochemistry
Out of the collected tumor samples were randomly selected glioblastoma and astrocytoma those were used to prepare 15 μm thick cryosections on Shannon Cryotome E (Thermo-Scientific Waltham). The sections collected on SuperFrost Plus (VWR International) glass microscope slides were left to air dry. After that, the sections were fixed by immersion in methanol for 10 min. The blocking-solution 2 (BS2), consisting of PBS supplemented with 1% (V/W) Triton X-100 (Sigma) and 2 mg/ml BSA, was layered on sections to prevent the unspecific protein binding activity for 60 min. Subsequently, the sections were incubated at 4 °C for overnight with a mixture of primary antibodies that were diluted in BS2: rabbit anti-PC, 1:250 and mouse anti-GFAP, 1:250. Prior to the application of secondary antibodies, the sections were washed 3 × 10 min in TBS enriched with 1% (V/V) Triton X-100. Secondary antibodies: goat anti-rabbit linked with Alexa Fluor 488 (1:1000; Invitrogen) and goat anti-mouse linked with Alexa Fluor 633 (1:1000, Invitrogen) were mixed in BS2 and were applied for 90 min. Subsequently, slides were washed three times in PBS. During the second washing step, PBS was supplemented with 5 µg/ml DAPI (Sigma) to visualize the cell nuclei. Finally, slides were rinsed with H2O and mounted with Fluoroshield Mounting Medium (Sigma). Only secondary antibodies were used for preparation of negative controls.
Microscopic Analysis
For imaging samples from glioblastoma and astrocytoma frozen sections a Zeiss Axio Examiner/LSM 880 confocal system (Carl Zeiss, Jena, Germany) with a Zeiss Plan-Apochromat 40 × /1.3 Oil DIC M27 objective and Zeiss Zen Black software was used. The 405 nm diode was used to visualize the cell nuclei (DAPI; Amax = 359 nm and Emax = 457 nm); argon 488 nm laser (Alexa Fluor 488; Amax 494 nm, Emax 519 nm) was used to visualize the PC and the 633 nm laser to visualize GFAP in samples (Alexa Fluor 633; Amax = 621 nm, Emax = 639 nm). Images were acquired with a resolution of 2048 × 2048 pixels, 1388 × 1040 pixel size and with a pinhole of 1.0 AU. A 2.5 × zoom was used for a more detailed view. The resulting images were processed using Zeiss Zen Blue software (Zeiss).
Statistical Analysis
The results are presented as mean ± SEM. The analysis of variance (ANOVA) test was performed to test the difference among the obtained values. The statistical analysis was performed with the software GraphPad Prism version 9.0.2 (GraphPad Software).
Data Availability
All data generated or analysed during this study are included in this published article [and its supplementary information files]. Enquiries about data availability should be directed to the authors.
References
Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41:211–218. https://doi.org/10.1016/j.tibs.2015.12.001
Patra KC, Hay N (2014) The pentose phosphate pathway and cancer. Trends Biochem Sci 39:347–354. https://doi.org/10.1016/j.tibs.2014.06.005
Anderson NM, Mucka P, Kern JG, Feng H (2018) The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell 9:216–237. https://doi.org/10.1007/s13238-017-0451-1
Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23:27–47. https://doi.org/10.1016/j.cmet.2015.12.006
Pavlova NN, Zhu J, Thompson CB (2022) The hallmarks of cancer metabolism: still emerging. Cell Metab. https://doi.org/10.1016/j.cmet.2022.01.007
Brunengraber H, Roe CR (2006) Anaplerotic molecules: current and future. J Inherit Metab Dis 29:327–331. https://doi.org/10.1007/s10545-006-0320-1
Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35:427–433. https://doi.org/10.1016/j.tibs.2010.05.003
Choi Y-K, Park K-G (2018) Targeting glutamine metabolism for cancer treatment. Biomol Ther 26:19–28. https://doi.org/10.4062/biomolther.2017.178
Zhao Y, Zhao X, Chen V et al (2019) Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo. Sci Rep 9:19180. https://doi.org/10.1038/s41598-019-55718-2
Cluntun AA, Lukey MJ, Cerione RA, Locasale JW (2017) Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer 3:169–180. https://doi.org/10.1016/j.trecan.2017.01.005
Cheng T, Sudderth J, Yang C et al (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci 108:8674–8679. https://doi.org/10.1073/pnas.1016627108
Phannasil P, Thuwajit C, Warnnissorn M et al (2015) Pyruvate carboxylase is up-regulated in breast cancer and essential to support growth and invasion of MDA-MB-231 cells. PLoS ONE 10:e0129848. https://doi.org/10.1371/journal.pone.0129848
Sellers K, Fox MP, Bousamra M et al (2015) Pyruvate carboxylase is critical for non–small-cell lung cancer proliferation. J Clin Invest 125:687–698. https://doi.org/10.1172/JCI72873
Christen S, Lorendeau D, Schmieder R et al (2016) Breast cancer-derived lung metastases show increased pyruvate carboxylase-dependent anaplerosis. Cell Rep 17:837–848. https://doi.org/10.1016/j.celrep.2016.09.042
Phannasil P, Ansari IH, El Azzouny M et al (2017) Mass spectrometry analysis shows the biosynthetic pathways supported by pyruvate carboxylase in highly invasive breast cancer cells. Biochim Biophys Acta BBA - Mol Basis Dis 1863:537–551. https://doi.org/10.1016/j.bbadis.2016.11.021
Lin Q, He Y, Wang X et al (2020) Targeting pyruvate carboxylase by a small molecule suppresses breast cancer progression. Adv Sci 7:1903483. https://doi.org/10.1002/advs.201903483
Gondáš E, Kráľová Trančíková A, Majerčíková Z et al (2021) Expression of pyruvate carboxylase in cultured human astrocytoma, glioblastoma and neuroblastoma cells. Gen Physiol Biophys 40:127–135. https://doi.org/10.4149/gpb_2021003
Jitrapakdee S, Maurice MST, Rayment I et al (2008) Structure, mechanism and regulation of pyruvate carboxylase. Biochem J. https://doi.org/10.1042/BJ20080709
Kiesel VA, Sheeley MP, Coleman MF et al (2021) Pyruvate carboxylase and cancer progression. Cancer Metab 9:20. https://doi.org/10.1186/s40170-021-00256-7
Owen OE, Kalhan SC, Hanson RW (2002) The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem 277:30409–30412. https://doi.org/10.1074/jbc.R200006200
Shi L, Tu BP (2015) Acetyl-CoA and the regulation of metabolism: mechanisms and consequences. Curr Opin Cell Biol 33:125–131. https://doi.org/10.1016/j.ceb.2015.02.003
Borst P (2020) The malate-aspartate shuttle (Borst cycle): how it started and developed into a major metabolic pathway. IUBMB Life 72:2241–2259. https://doi.org/10.1002/iub.2367
Zhang X, Yang S, Chen J, Su Z (2018) Unraveling the regulation of hepatic gluconeogenesis. Front Endocrinol 9:802. https://doi.org/10.3389/fendo.2018.00802
Wilmanski T, Zhou X, Zheng W et al (2017) Inhibition of pyruvate carboxylase by 1α,25-dihydroxyvitamin D promotes oxidative stress in early breast cancer progression. Cancer Lett 411:171–181. https://doi.org/10.1016/j.canlet.2017.09.045
Shinde A, Wilmanski T, Chen H et al (2018) Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer. Breast Cancer Res 20:76. https://doi.org/10.1186/s13058-018-1008-9
Cesar M, Hamprecht B (1995) Immunocytochemical examination of neural rat and mouse primary cultures using monoclonal antibodies raised against pyruvate carboxylase. J Neurochem 64:2312–2318. https://doi.org/10.1046/j.1471-4159.1995.64052312.x
Cetinbas NM, Sudderth J, Harris RC et al (2016) Glucose-dependent anaplerosis in cancer cells is required for cellular redox balance in the absence of glutamine. Sci Rep 6:32606. https://doi.org/10.1038/srep32606
Tichy J, Spechtmeyer S, Mittelbronn M et al (2016) Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J Neurooncol 126:361–369. https://doi.org/10.1007/s11060-015-1978-8
Ngamkham J, Thuwajit C, Thuwajit P et al (2020) Overexpression of pyruvate carboxylase is correlated with colorectal cancer progression and supports growth of invasive colon cancer HT-29 cell line. Anticancer Res 40:6285–6293. https://doi.org/10.21873/anticanres.14649
Lau AN, Li Z, Danai LV et al (2020) Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. Elife 9:e56782. https://doi.org/10.7554/eLife.56782
Gondas E, Hives M, Kliment J et al (2022) The ubiquitous expression of pyruvate carboxylase among human prostate tumors. Bratisl Med J 123:487–490. https://doi.org/10.4149/BLL_2022_077
Marin-Valencia I, Yang C, Mashimo T et al (2012) Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 15:827–837. https://doi.org/10.1016/j.cmet.2012.05.001
Inigo M, Deja S, Burgess SC (2021) Ins and outs of the TCA cycle: the central role of anaplerosis. Annu Rev Nutr 41:19–47. https://doi.org/10.1146/annurev-nutr-120420-025558
Baranovičová E, Galanda T, Galanda M et al (2019) Metabolomic profiling of blood plasma in patients with primary brain tumours: basal plasma metabolites correlated with tumour grade and plasma biomarker analysis predicts feasibility of the successful statistical discrimination from healthy subjects - a preliminary study. IUBMB Life 71:1994–2002. https://doi.org/10.1002/iub.2149
Jitrapakdee S, St Maurice M, Rayment I et al (2008) Structure, mechanism and regulation of pyruvate carboxylase. Biochem J 413:369–387. https://doi.org/10.1042/BJ20080709
Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10:671–684. https://doi.org/10.1038/nrd3504
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl) 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Gondáš E, Kráľová Trančíková A, Baranovičová E et al (2022) Expression of 3-methylcrotonyl-CoA carboxylase in brain tumors and capability to catabolize leucine by human neural cancer cells. Cancers 14:585. https://doi.org/10.3390/cancers14030585
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685. https://doi.org/10.1038/227680a0
Acknowledgments
This work was supported by projects: VEGA 1/0255/20, and by the Slovak Research and Development Agency under the contract No. APVV-18-0088 and APVV-19-0033. The authors are very grateful to Bernd Hamprecht (University of Tuebingen, Germany) for the generous gift of anti-PC serum.
Funding
Funding was provided by Agentúra na Podporu Výskumu a Vývoja (APVV-18-0088, and APVV-19-0033) and Slovenská Akadémia Vied (VEGA 1/0255/20).
Author information
Authors and Affiliations
Contributions
The following statements should be used Conceptualization, EG and RM; methodology, EG, AKT and RM; formal analysis, RM; investigation, EG; resources, KD, TG, JH and RM; data curation, AKT and RM; writing—original draft preparation, EG and RM; supervision, PR; funding acquisition, JH and DD. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gondáš, E., Kráľová Trančíková, A., Dibdiaková, K. et al. Immunodetection of Pyruvate Carboxylase Expression in Human Astrocytomas, Glioblastomas, Oligodendrogliomas, and Meningiomas. Neurochem Res 48, 1728–1736 (2023). https://doi.org/10.1007/s11064-023-03856-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-023-03856-5